Oncology

News Oncology

• Moffitt researchers find potential new therapeutic target for treating non-small cell lung cancer

  Researchers at Moffitt Cancer Center have found a potential targeted therapy for patients with tobacco-associated non-small cell lung cancer. It is based on the newly identified oncogene IKBKE, which helps regulate immune response. The study appeared in the online issue of Oncogene. The IKBKE gene i more

• MagForce to radically enforce market set up strategy with new management team

  MagForce AG announced additions to the management board and further measures to enforce commercialization of NanoTherm® therapy. Thus, focussing on establishing the NanoTherm® therapy in the oncology market as well as on its commercialization for near-term value generation.In the short to mid term, more

• Dyax Corp. and Kadmon sign strategic licensing agreement for antibody inhibitor DX-2400

  Dyax Corp. and Kadmon Corporation, LLC (Kadmon) announced that they have entered into a strategic licensing agreement in which Kadmon has been granted an exclusive worldwide license for the development and commercialization of the fully human monoclonal antibody DX-2400, a potent and selective antib more

White papers Oncology

• Analysis of the DNA Methylation Patterns at the BRCA1 CpG Island
  

  Germ-line alterations of the BRCA1 gene confer a lifetime risk of 40% for ovarian cancers and of 40%-80% for ­breast cancers. It is likely that BRCA1 acts as a tumor suppressor gene. BRCA1 involvement in breast cancers does not seem to be restricted to familial cancers. Despite the absence of somatic mutations in the breast tissues, a down regulation of BRCA1 expression is associated with malignancy in human sporadic breast cancers. more

• Interference and HAMA problems
  

  Immunoassays are bioanalytical methods based on antibodies. These include ELISA, EIA, RIA, Western blotting, protein arrays, lateral flow assays (immuno-chromatography), immunohistochemistry or immuno-PCR. Antibodies detect the substances (analytes) in immunoassays. This detection is always highly specific and only the analytes are detected and bound. This is the theory! Practically any antibody not only binds its analyte. It also binds several other substances, but with very different affinities. more

• Alliances in Drug Discovery - The Chemical Element
  

  Alliances have evolved into a critical cornerstone of R&D strategy in the global pharmaceutical industry. No other industry has been leveraging this business model as successfully as the global pharmaceutical industry in its drive for innovation and success. Over three thousand deals amounting to a cumulative payout of US$ 17bn have been signed by pharmaceutical and biotech players in a span of two decades. In the past five years the industry's mania to develop new generation blockbuster drugs has taken on a new sense of urgency as 64% of the alliance value was inked and paid out during the period. more

Publications Oncology

• Genetic testing insurance coverage trends: a review of publicly available policies from the largest US payers

  Aim: Health plan coverage policies can influence utilization of genetic tests. Our goal was to characterize the current state of test-related policies from US private payers. Methods: We searched the public websites of 206 insurers for coverage policies. We documented the number of policies, tests m more

• Evidence for a Functionally Relevant Rocaglamide Binding Site on the eIF4A–RNA Complex

  Translation initiation is an emerging target in oncology and neurobiology indications. Naturally derived and synthetic rocaglamide scaffolds have been used to interrogate this pathway; however, there is uncertainty regarding their precise mechanism(s) of action. We exploited the genetic tractability more

• Statins and Cancer‐Related Mortality: An Open Question

  HMG‐CoA reductase inhibitors, statins and pleiotropic effects have been associated with both increased and decreased cancer risk. This letter intends to contribute to ascertaining the real role of statins in cancer since there are conflicting results in the literature1. In the last volume of The L more

Market studies Oncology

• Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - February 2012

  Introduction GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - February 2012” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The repor more

• IDL Biotech AB (IDL B) - Financial and Strategic SWOT Analysis Review

  IDL Biotech AB (IDL Biotech AB) is a Sweden based biotechnology company engaged in developing, manufacturing and marketing of in vitro diagnostics within the areas of oncology and bacteriology. The product pipeline of the company consists of TPS, TPAcyk, MonoTotal and UBC, which are cytokeratin tumo more

• Uzbekistan Pharmaceuticals and Healthcare Report Q2 2012

  BMI View: Uzbekistan’s pharmaceutical market remains one of the fastest growing in the Central and Eastern Europe (CEE) region and its population and currently low levels of per capita pharmaceutical spending gives it the greatest long-term growth potential of any Central Asian market. BMI forecasts more

Websites Oncology